1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Ever Supreme Bio Technology Co., Ltd.

Ever Supreme Bio Technology Co., Ltd.

TTPEX:6712
152.00
TWD
-1.00
(-0.65%)
4.91EPS
32.26P/E
15.97BMarket Cap
Nov 17Next Earn
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
0.13
0.82
4.63
6.59
8.03
10.02
11.02
11.22
Basic EPS, GAAP
-0.03
-0.54
-0.85
-1.09
-1.24
3.9
2.11
5.71
3.94
4.65
4.91
Free Cash Flow per Basic Share
-0.1
-0.69
-1.2
-1.5
-2.31
1.38
3.3
4.4
4.67
5.75
6.55
Dividend per Share
- -
- -
- -
- -
- -
- -
3.25
1.44
4.72
4.42
- -
Book Value per Share
1.7
5.98
10.82
9.83
9.07
19.98
18.83
19.78
19.26
16.6
27.93
Tangible Book Value per Share
1.7
5.91
10.73
9.72
8.96
19.86
18.7
19.66
19.15
16.45
17.03
Basic Weighted Avg Shares
15
57
81
86
86
95
95
94
93
92
96
Sales/Revenue/Turnover
- -
- -
- -
11
71
439
628
758
934
1,018
1,081
Operating Margin (%)
- -
- -
- -
-1,252.31
-222.54
26.48
45.23
44.53
49.86
43.14
44.15
Depreciation Expense
- -
1
7
17
32
36
36
32
31
23
23
Net Income, GAAP
- -
-31
-69
-94
-107
370
201
539
367
429
473
Effective Tax Rate (%)
- -
- -
- -
- -
- -
6.86
24
13.42
20.29
18.1
18.46
Profit Margin (%)
- -
- -
- -
-870.87
-151.32
84.22
31.99
71.12
39.33
42.2
43.77
Working Capital
98
307
789
598
438
1,370
1,292
1,289
894
330
597
LT Debt
- -
- -
- -
32
33
23
13
1
1
28
23
Total Equity
100
349
931
846
781
1,898
1,792
1,843
1,794
1,527
2,814
Return on Invested Capital (%)
- -
- -
- -
- -
- -
7.79
11.43
15.74
19.74
20.68
17.61
Return on Capital (%)
- -
- -
- -
- -
- -
26.86
10.75
29.49
20.15
25.59
21.89
Return on Common Equity (%)
- -
-13.65
-10.74
-10.6
-13.13
27.6
10.88
29.68
20.19
25.86
23.35

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
10
10
210
LT Borrowings
- -
- -
- -
LT Finance Leases
28
25
23
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
92
102
101
Market Capitalization
14,366
13,472
15,966

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
753
1,345
1,270
Cash, Cash Equivalents & STI
436
1,168
1,057
Accounts Receivable, Net
229
88
121
Inventories
76
71
72
Total Current Liabilities
423
765
673
Payables & Accruals
- -
- -
- -
ST Debt
10
10
210
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
24.55%
-14.92%
Free Cash Flow
- -
6.56%
22.04%
Net Income, GAAP
- -
-67.58%
16.93%
Sales/Revenue/Turnover
- -
123.51%
8.96%
Total Cash Common Dividend
- -
- -
-7.32%

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
163
178
248
344
934
2025
178
221
263
355
1,018
2026
190
272
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.24
1.24
0.2
2.26
3.94
2025
0.95
0.98
1.43
1.3
4.65
2026
1.32
0.89
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
4.72
2025
- -
- -
- -
- -
4.42
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Wei Liang Huang
Full Time Employees
88
Sector
Health technology
Industry
Biotechnology
Address
No. 30, Keya Road Taichung TX Taiwan
IPO Date
Jan 8, 2021
Website
ever-supreme.com.tw
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Ever Supreme Bio Technology Co., Ltd (6712.TWO) is a Taiwan-based biotechnology company that specializes in the research, development, manufacturing, and sale of bio-functional materials and health-related products. The company offers a range of core products including nano-silver antimicrobial agents, far-infrared ceramic powders, negative ion products, health supplements such as probiotics and collagen formulations, and bio-based skincare and personal care items; it also provides custom OEM/ODM services for functional textiles, medical fabrics, and environmental purification solutions. Operations focus on the health and wellness sector, targeting consumer markets in Asia with emphasis on antimicrobial technologies and functional materials for apparel, healthcare, and daily consumer goods. Founded in 2001 and headquartered in Taoyuan City, Taiwan, the company maintains production facilities primarily in Taiwan and distributes products across domestic and international markets including China, Southeast Asia, and select global regions through partnerships and e-commerce channels. It operates as an independent entity listed on the Taipei Exchange, with no major disclosed subsidiaries or parent relationships. In recent developments, Ever Supreme Bio Technology expanded its product portfolio with new launches of advanced probiotic supplements and silver ion-based antimicrobial coatings in 2024, aimed at post-pandemic hygiene demands. The company secured strategic collaborations with textile manufacturers for integrating bio-functional materials into sustainable fabrics and reported revenue growth from health supplement sales amid rising consumer interest in immunity-boosting products. No significant acquisitions, funding rounds, or reorganizations have been announced in the past two years, reflecting steady operational focus on core bio-technology innovations.